title: Sensitization of Gram-negative bacteria to rifampin and OAK combinations.
abstract: While individually inefficient against Gram-negative bacteria, in-vitro combinations of rifampin and OAK were mutually synergistic since sub-minimal inhibitory concentrations of one compound have potentiated the other by 2-4 orders of magnitude. Synergy persisted in-vivo as single-dose systemic treatment of Klebsiella infected mice resulted in 10-20% versus 60% survival, respectively accomplished by individual and combined compounds. This outcome was achieved without drug formulation, rather, pharmacokinetic considerations have inspired the therapeutic regimen.
authors.affiliation: Department of Biotechnology &Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
authors.forename: Joanna
authors.initials: J
authors.lastname: Jammal
authors.affiliation: Department of Biotechnology &Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
authors.forename: Fadia
authors.initials: F
authors.lastname: Zaknoon
authors.affiliation: Department of Biotechnology &Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
authors.forename: Galoz
authors.initials: G
authors.lastname: Kaneti
authors.affiliation: Department of Biotechnology &Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
authors.forename: Keren
authors.initials: K
authors.lastname: Goldberg
authors.affiliation: Department of Biotechnology &Food Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
authors.forename: Amram
authors.initials: A
authors.lastname: Mor
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D009842:Oligopeptides / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D009842:Oligopeptides; D012293:Rifampin